BioCentury | Dec 7, 2019
Product Development

U.S. biosimilars glass--half full or half empty?

...Former), infliximab (Generic), Remicade (Other) Novartis AG Amgen Inc. Samsung Bioepis Co. Ltd. Mylan N.V. Sandoz Ltd. IQVia Holdings Inc. Coherus BioSciences Inc. Kaiser Permanente Northern California Merck...
BioCentury | Nov 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: October 2018

...transcription factor 1 (SIM1) A SNP on SIM1 could help predict the risk of ED Kaiser Permanente Northern California...
BioCentury | Oct 11, 2018
Distillery Techniques

Biomarkers

...Proc. Natl. Acad. Sci. USA ; published online Oct. 8, 2018 doi:10.1073/pnas.1809872115 CONTACT: Eric Jorgenson, Kaiser Permanente Northern California...
...Calif. email: eric.jorgenson@kp.org CONTACT: Stephen K. Van Den Eeden, same affiliation as above email: stephen.vandeneeden@kp.org Claire Quang Kaiser Permanente Northern California SIM...
BioCentury | Mar 20, 2018
Politics & Policy

FDA, Kaiser evaluating PROs in pancreatic cancer patients

...records at a large healthcare system capture those outcomes. The study will include data from Kaiser Permanente Northern California...
BioCentury | Feb 15, 2017
Distillery Techniques

Biomarkers

...Nat. Commun. ; published online Jan. 31, 2017 doi:10.1038/ncomms14248 CONTACT: Stephen K. Van Den Eeden, Kaiser Permanente Northern California...
BioCentury | Jan 26, 2017
Strategy

Deep roots

...with other large healthcare systems around the country interested in replicating Geisinger’s model, such as Kaiser Permanente Northern California...
...American College of Medical Genetics and Genomics (ACMG), Bethesda, Md. Geisinger Health System, Danville, Pa. Kaiser Permanente Northern California...
BioCentury | Jul 4, 2011
Regulation

Moving past Actos

...University of Pennsylvania and Kaiser Permanente , the retrospective study includes 193,099 patients from the Kaiser Permanente Northern California...
BioCentury | Jun 20, 2011
Clinical News

Actos pioglitazone regulatory update

...observational trial is evaluating new diagnoses of bladder cancer in 193,099 diabetic patients on the Kaiser Permanente Northern California...
...observational trial is evaluating new diagnoses of bladder cancer in 193,099 diabetic patients on the Kaiser Permanente Northern California...
BioCentury | Jun 20, 2011
Clinical News

Actos pioglitazone: Postmarketing study data

...observational trial is evaluating new diagnoses of bladder cancer in 193,099 diabetic patients on the Kaiser Permanente Northern California...
BioCentury | Jun 16, 2011
Company News

FDA warns of bladder cancer with Actos

...observational trial is evaluating new diagnoses of bladder cancer in 193,099 diabetic patients on the Kaiser Permanente Northern California...
Items per page:
1 - 10 of 17
BioCentury | Dec 7, 2019
Product Development

U.S. biosimilars glass--half full or half empty?

...Former), infliximab (Generic), Remicade (Other) Novartis AG Amgen Inc. Samsung Bioepis Co. Ltd. Mylan N.V. Sandoz Ltd. IQVia Holdings Inc. Coherus BioSciences Inc. Kaiser Permanente Northern California Merck...
BioCentury | Nov 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: October 2018

...transcription factor 1 (SIM1) A SNP on SIM1 could help predict the risk of ED Kaiser Permanente Northern California...
BioCentury | Oct 11, 2018
Distillery Techniques

Biomarkers

...Proc. Natl. Acad. Sci. USA ; published online Oct. 8, 2018 doi:10.1073/pnas.1809872115 CONTACT: Eric Jorgenson, Kaiser Permanente Northern California...
...Calif. email: eric.jorgenson@kp.org CONTACT: Stephen K. Van Den Eeden, same affiliation as above email: stephen.vandeneeden@kp.org Claire Quang Kaiser Permanente Northern California SIM...
BioCentury | Mar 20, 2018
Politics & Policy

FDA, Kaiser evaluating PROs in pancreatic cancer patients

...records at a large healthcare system capture those outcomes. The study will include data from Kaiser Permanente Northern California...
BioCentury | Feb 15, 2017
Distillery Techniques

Biomarkers

...Nat. Commun. ; published online Jan. 31, 2017 doi:10.1038/ncomms14248 CONTACT: Stephen K. Van Den Eeden, Kaiser Permanente Northern California...
BioCentury | Jan 26, 2017
Strategy

Deep roots

...with other large healthcare systems around the country interested in replicating Geisinger’s model, such as Kaiser Permanente Northern California...
...American College of Medical Genetics and Genomics (ACMG), Bethesda, Md. Geisinger Health System, Danville, Pa. Kaiser Permanente Northern California...
BioCentury | Jul 4, 2011
Regulation

Moving past Actos

...University of Pennsylvania and Kaiser Permanente , the retrospective study includes 193,099 patients from the Kaiser Permanente Northern California...
BioCentury | Jun 20, 2011
Clinical News

Actos pioglitazone regulatory update

...observational trial is evaluating new diagnoses of bladder cancer in 193,099 diabetic patients on the Kaiser Permanente Northern California...
...observational trial is evaluating new diagnoses of bladder cancer in 193,099 diabetic patients on the Kaiser Permanente Northern California...
BioCentury | Jun 20, 2011
Clinical News

Actos pioglitazone: Postmarketing study data

...observational trial is evaluating new diagnoses of bladder cancer in 193,099 diabetic patients on the Kaiser Permanente Northern California...
BioCentury | Jun 16, 2011
Company News

FDA warns of bladder cancer with Actos

...observational trial is evaluating new diagnoses of bladder cancer in 193,099 diabetic patients on the Kaiser Permanente Northern California...
Items per page:
1 - 10 of 17